Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir

British Journal of Pharmacology

Volumn 160, Issue 5, 2010, Pages 1224-1233

  Van Waterschoot, R A B ^a   Ter Heine, R ^b   Wagenaar, E ^a   Van Der Kruijssen, C M M ^a   Rooswinkel, R W ^a   Huitema, A D R ^b   Beijnen, J H ^b   Schinkel, A H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

CYP3A; Intestinal metabolism; Lopinavir; MDR1); MRP2 (ABCC2); P glycoprotein (ABCB1

Indexed keywords

CYTOCHROME P450 3A; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; RITONAVIR; CYP3A4 PROTEIN, HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; PYRIMIDINONE DERIVATIVE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; INTESTINE; KIDNEY CELL; LIVER; LIVER METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BIOAVAILABILITY; COMPARATIVE STUDY; DOG; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; GENETICS; HUMAN; INBRED MOUSE STRAIN; METABOLISM;

ANIMALS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; DOGS; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; INTESTINES; LIVER; LOPINAVIR; MALE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PYRIMIDINONES; RITONAVIR;

EID: 77953212109     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00759.x     Document Type: Article

References (50)

1. Agarwal S, Pal D, Mitra AK (2007). Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. Int J Pharm 339 : 139 147.
2. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1 S1 S254.
3. Benet LZ, Cummins CL (2001). The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 50 : S3 S11.
4. Bergshoeff AS, Fraaij PL, Ndagijimana J, Verweel G, Hartwig NG, Niehues T et al. (2005). Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. J Acquir Immune Defic Syndr 39 : 63 68.
5. Bertz R, Foit C, Burt D, Grebner K, Marsh T, Bernstein B et al. (2002). Assessment of the effect of nevirapine on the pharmacokinetics of lopinavir/ritonavir (Kaletra) after multiple dosing in HIV-infected adults. Int Conf AIDS 14 : abstract no. 4565.
6. van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, De Smet PA, Burger DM (2006). Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev 38 : 477 514.
7. van den Bout-van den Beukel CJ, Bosch ME, Burger DM, Koopmans PP, van der Ven AJ (2008). Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications. AIDS 22 : 1243 1244.
8. Corona G, Vaccher E, Sandron S, Sartor I, Tirelli U, Innocenti F et al. (2008). Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther 83 : 601 606.
9. Crommentuyn KM, Mulder JW, Sparidans RW, Huitema AD, Schellens JH, Beijnen JH (2004). Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clin Infect Dis 38 : 73 75.
10. Crommentuyn KM, Kappelhoff BS, Mulder JW, Mairuhu AT, van Gorp EC, Meenhorst PL et al. (2005). Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 60 : 378 389.
11. Dresser GK, Spence JD, Bailey DG (2000). Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38 : 41 57.
12. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J (1999). HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 57 : 1147 1152.
13. Evers R, Cnubben NH, Wijnholds J, van Deemter L, van Bladeren PJ, Borst P (1997). Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett 419 : 112 116.
14. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC et al. (1998). Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101 : 1310 1319.
15. Falcon RW, Kakuda TN (2008). Drug interactions between HIV protease inhibitors and acid-reducing agents. Clin Pharmacokinet 47 : 75 89.
16. Fulco PP, Zingone MM, Higginson RT (2008). Possible antiretroviral therapy-warfarin drug interaction. Pharmacotherapy 28 : 945 949.
17. Garmire LX, Hunt CA (2008). In silico methods for unraveling the mechanistic complexities of intestinal absorption: metabolism-efflux transport interactions. Drug Metab Dispos 36 : 1414 1424.
18. Guengerich FP (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39 : 1 17.
19. Guiard-Schmid JB, Poirier JM, Meynard JL, Bonnard P, Gbadoe AH, Amiel C et al. (2003). High variability of plasma drug concentrations in dual protease inhibitor regimens. Antimicrob Agents Chemother 47 : 986 990.
20. Guo A, Marinaro W, Hu P, Sinko PJ (2002). Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 30 : 457 463.
21. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS (1999). Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56 : 383 389.
22. ter Heine R, Alderden-Los CG, Rosing H, Hillebrand MJ, van Gorp EC, Huitema AD et al. (2007). Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 21 : 2505 2514.
23. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY et al. (2007). Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117 : 3583 3592.
24. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH (2001). P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 59 : 806 813.
25. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH et al. (2002). Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16 : 2295 2301.
26. Ito K, Kusuhara H, Sugiyama Y (1999a). Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach. Pharm Res 16 : 225 231.
27. Ito S, Woodland C, Sarkadi B, Hockmann G, Walker SE, Koren G (1999b). Modeling of P-glycoprotein-involved epithelial drug transport in MDCK cells. Am J Physiol 277 : F84 F96.
28. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM et al. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101 : 289 294.
29. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW (2008). Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 47 : 570 578.
30. Kivisto KT, Niemi M, Fromm MF (2004). Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 18 : 621 626.
31. Kolars JC, Awni WM, Merion RM, Watkins PB (1991). First-pass metabolism of cyclosporin by the gut. Lancet 338 : 1488 1490.
32. Kumar GN, Jayanti V, Lee RD, Whittern DN, Uchic J, Thomas S et al. (1999). In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab Dispos 27 : 86 91.
33. Lagas JS, Vlaming ML, van Tellingen O, Wagenaar E, Jansen RS, Rosing H et al. (2006). Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res 12 : 6125 6132.
34. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54 : 1271 1294.
35. van der Lee M, Sankatsing R, Schippers E, Vogel M, Fatkenheuer G, van der Ven A et al. (2007). Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther 12 : 1127 1132.
36. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J et al. (2002). Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62 : 162 171.
37. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA et al. (1997). Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99 : 2545 2553.
38. Mandlekar S, Hong JL, Kong AN (2006). Modulation of metabolic enzymes by dietary phytochemicals: a review of mechanisms underlying beneficial versus unfavorable effects. Curr Drug Metab 7 : 661 675.
39. Paine MF, Oberlies NH (2007). Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin Drug Metab Toxicol 3 : 67 80.
40. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP et al. (1996). First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60 : 14 24.
41. Schinkel AH, Jonker JW (2003). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55 : 3 29.
42. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ et al. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94 : 4028 4033.
43. Thummel KE (2007). Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest 117 : 3173 3176.
44. Thummel KE, Wilkinson GR (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38 : 389 430.
45. Vlaming ML, Mohrmann K, Wagenaar E, de Waart DR, Oude Elferink RP, Lagas JS et al. (2006). Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318 : 319 327.
46. van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song J-Y et al. (2009). Absence of both CYP3A and P-gp dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 69 : 8996 9002.
47. Watkins PB (1997). The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27 : 161 170.
48. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ (2005). MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 19 : 1617 1625.
49. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY et al. (1995). Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58 : 492 497.
50. Zou L, Harkey MR, Henderson GL (2002). Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71 : 1579 1589.